Japan’s Mochida Pharma Lowers Sales Estimate For 2010
This article was originally published in PharmAsia News
Tokyo-based Mochida Pharmaceutical announces a midterm business plan for 2010, and the company estimates sales of ¥77 billion and ¥10.5 billion in profit. The sales goal is ¥5.5 billion lower than last year's actual result. Mochida will devote ¥10 billion to research and development. To reach the goals, Mochida plans to further strengthen strategic alliances, enter intractable diseases and cellular pharmaceutical areas and expand in the generics market. Mochida also plans to develop three drug candidates in domestic and overseas markets, focusing on core areas of diabetics and obesity, and sub-core area of chronic pain. (Click here for more - Japanese language
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.